SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Acumen Pharmaceuticals to Present ALTITUDE-AD Trial Data at CTAD

Acumen Pharmaceuticals says it will present preliminary baseline characteristics and data on care experiences and participation from its Phase 2 ALTITUDE-AD trial at the CTAD conference.

ABOS

Related stories